# Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

> **NCT03937219** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Exelixis** · enrollment: 855 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **DRUG:** Cabozantinib-matched placebo

## Key facts

- **NCT ID:** NCT03937219
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-25
- **Primary completion:** 2022-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 855 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03937219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03937219, "Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03937219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*